Provides software solutions for healthcare, cannabis, and government sectors. Offers data-driven insights and predictive analytics. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 16% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 2.2× for every dollar of annual revenue.
Analysts' average target sits 107% above today's price.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 85% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 16% a year on average.
Sales run at $30.3M a year. A small number, but proof the product has real buyers.
There is $31.6M in the vault; even if every debt were paid off, $31.5M would remain.
A loss of $2.9M against $30.3M in annual sales.
Since the drop from its peak, buyer appetite hasn’t come back.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.